Drug Policy Watch · State Brief 2026

Arkansas

Snapshot (structured)

Adult-use cannabis: Illegal. Voters rejected Issue 4 in November 2022 (about 56 percent no).
Medical cannabis: Legal since 2016 (Amendment 98); retail sales began May 2019.
Home grow: Not permitted for any user, medical or otherwise.
Intoxicating hemp / hemp THC: Banned. Act 629 of 2023 plus Act 934 of 2025; enforcement live as of April 2026.
Psychedelics: Illegal. No decriminalization or therapeutic-access law; no advancing 2026 bills found.
Broad decriminalization: No. Possession remains criminalized.
Harm reduction: Partial. Naloxone access and fentanyl test strips legal; syringe services only impliedly permitted.
Governor (party): Sarah Huckabee Sanders (Republican).
Legislature control: Republican trifecta. House about 81-19 R, Senate about 29-6 R.
Citizen ballot initiatives allowed: Yes, including constitutional amendments by petition.
Enclosure pressure score: 4/5

Cannabis

Adult-use cannabis is illegal in Arkansas. Voters rejected the recreational legalization measure Issue 4 in November 2022, roughly 56 percent to 44 percent (Ballotpedia / MPP overview).

Medical cannabis has been legal since voters approved the Arkansas Medical Marijuana Amendment (Amendment 98) in November 2016, making Arkansas the first Bible Belt state to do so. Dispensary sales began in May 2019. Qualifying patients may purchase up to 2.5 ounces every 14 days, with conditions including cancer, glaucoma, PTSD, Crohn's disease, severe arthritis, and chronic pain (mmj.com guide; Arkansas DFA Medical Marijuana Commission).

Home grow is not permitted for any patient or consumer.

Market structure: The amendment caps the market at up to 40 dispensaries and 8 cultivators (AlphaRoot license guide). As of late 2025 there were about 38 licensed dispensaries operating (Marijuana Herald, Nov 2025). The registered patient count reached about 115,275 by March 2026 (Marijuana Herald, Mar 2026). Medical sales hit a record of about 291.1 million dollars in 2025 (Camden News, Feb 2026). Cannabis is taxed via a 6.5 percent state sales tax plus a 4 percent privilege tax (Cannabis CPA tax guide).

Key 2026 actions: The 2026 legislative session was a short fiscal session focused on the budget, and no cannabis bills were filed (mmj.com guide). The most consequential recent cannabis action was in 2025: Governor Sanders vetoed HB1889 (dispensary delivery and drive-through windows), one of the first vetoes of the 95th General Assembly, on the last day of the April 2025 session (Sanders veto letter; NORML).

Hemp

Intoxicating hemp and hemp-derived THC products are banned in Arkansas. The original prohibition, Act 629 of 2023, outlawed the sale and distribution of Delta-8, Delta-9, Delta-10, THC-O, and other intoxicating hemp compounds, but was tied up in litigation. On June 24, 2025, the U.S. Court of Appeals for the Eighth Circuit reversed a lower-court injunction and cleared statewide enforcement (cannabisregulations.ai; KATV). Within three months, the Department of Finance and Administration seized more than 6,000 illegal hemp products (Marijuana Moment).

Act 934 of 2025 expanded the ban. Governor Sanders signed it on April 21, 2026, and Attorney General Tim Griffin certified it on April 22, 2026, the certification triggering its effective date once final judgment in the litigation had issued (Arkansas AG news release; Arkansas Advocate; Arkansas Democrat-Gazette). Non-intoxicating CBD products generally remain legal.

Federal context: In November 2025, the Continuing Appropriations Act, 2026, rewrote the federal definition of hemp, capping total THC (including THCA and isomers) at 0.3 percent on a dry-weight basis and limiting products to no more than 0.4 milligrams of total THC per container, while banning synthesized cannabinoids such as Delta-8 and Delta-10. These federal restrictions take effect November 12, 2026 (Herb; Frier Levitt). Arkansas already prohibits these products at the state level, so it is positioned ahead of, rather than disrupted by, the federal deadline. The federal change reinforces Arkansas's existing posture rather than forcing new state action.

Psychedelics

Arkansas has no decriminalization or therapeutic-access framework for psychedelics. Psilocybin and similar substances remain controlled and illegal, and no psychedelic reform bills appear to have advanced in the legislature (recovered.org legal status; Microdose Movement tracker). The note that Arkansas classifies psilocybin as a state Schedule VI substance comes from a secondary tracker and is treated here as unconfirmed pending a primary statutory citation. No active 2026 psychedelic bills were identified; given the short 2026 fiscal session, the next realistic window for such legislation is the 2027 regular session.

Broader drug policy

Decriminalization: Arkansas has not decriminalized drug possession. Possession of controlled substances, including marijuana outside the medical program, remains a criminal offense (Nelson & Marks, Oct 2025).

Harm reduction: Fentanyl test strips were legalized by the Fentanyl Enforcement and Accountability Act of 2023, which carved single-use fentanyl test strips out of the paraphernalia definition (Association of Arkansas Counties). Naloxone is available over the counter through pharmacists, and free intramuscular naloxone is distributed by mail through Northwest Arkansas Harm Reduction (NEXT Distro). Syringe services programs are not explicitly authorized; free syringe distribution is not generally barred (except to minors), so SSPs are only impliedly permitted (NEXT Distro). Arkansas has two limited Good Samaritan protections, one for administering naloxone in good faith and one for 911 callers, but the overdose immunity does not extend to paraphernalia charges (NEXT Distro). A 2025-2026 federal SAMHSA guidance change blocks federal funds for fentanyl test strips, syringes, and smoking supplies while still allowing naloxone, which may pressure state and local programs that rely on federal dollars (NACo).

Sentencing and expungement: Arkansas's Criminal Record Sealing Act allows people with certain non-violent Class C or D drug felonies to petition for sealing after completing their sentence, and many first-time misdemeanor possession charges are eligible for sealing once penalties are complete. Felony possession may be sealed after completing a residential drug treatment program and probation; violent, gun, serious sexual, and Class Y felonies are excluded (ccresourcecenter.org; Nelson & Marks, Aug 2025). In 2025, SB485 addressed how courts may impose probation conditions, requiring them to be narrowly tailored to rehabilitation, public safety, and the defendant's risks and needs (sponsor unconfirmed) (ccresourcecenter.org).

Overdose and treatment: Treatment-oriented diversion exists for some first-time and minor possession cases, and felony sealing is conditioned on completing residential treatment, reflecting a treatment-as-pathway-to-relief model rather than broad decriminalization (Nelson & Marks, Nov 2025).

Political landscape

Governor: Sarah Huckabee Sanders (Republican), seeking a second term in 2026 and a strong favorite (Arkansas Advocate). Arkansas is a Republican trifecta. Following the 2024 elections, Republicans hold roughly 81-19 in the House and 29-6 in the Senate (Ballotpedia: Arkansas General Assembly).

Reform dynamics: The clearest reform-leaning figure on cannabis is Republican Rep. Aaron Pilkington, who sponsored the vetoed medical-cannabis access bill HB1889 and publicly objected to the governor's veto rationale (Arkansas Times). The most influential opponent of cannabis expansion is Governor Sanders, who has vetoed access-expansion bills, framing them as expanding marijuana availability (Sanders veto letter). On hemp, Attorney General Tim Griffin has been the lead enforcer, certifying Act 934 and championing the ban (Arkansas AG news release). Specific key committee assignments for drug-policy bills are unconfirmed here; check the Arkansas General Assembly committees page.

Ballot initiatives

Arkansas allows citizen-initiated statutes and constitutional amendments by petition. The most recent cannabis ballot effort was the 2024 Arkansas Medical Marijuana Amendment, sponsored by Arkansans for Patient Access, which submitted about 111,400 signatures. It appeared on the November 2024 ballot, but the Arkansas Supreme Court ruled the votes would not be counted because of misleading ballot language (Ballotpedia; Fox 13 Memphis). That measure would have broadened who can certify patients, expanded qualifying conditions, made cards valid for three years, allowed pre-rolled joints, and included a trigger ending state prohibition if the federal government legalizes. No confirmed 2026 cannabis or psychedelic ballot measure was identified in current sources; treat the absence as likely but not certain given fluid petition activity.

Equity and expungement

Arkansas's medical-cannabis law contains no meaningful social-equity licensing program; the small, capped license pool (40 dispensaries, 8 cultivators) with high capital requirements has favored well-funded operators rather than equity applicants. On records, Arkansas uses petition-based sealing rather than automatic expungement, so relief depends on individuals affirmatively petitioning and completing all conditions, which excludes those who cannot navigate the process or who have ineligible (violent, gun, Class Y) offenses (ccresourcecenter.org). There is no cannabis-specific automatic expungement tied to the medical program.

Market and barriers

Taxes: 6.5 percent state sales tax plus 4 percent privilege tax on medical cannabis (Cannabis CPA).
Cultivation license application fee: 15,000 dollars, plus proof of a 1,000,000 dollar surety bond or assets and at least 500,000 dollars in liquid assets (AlphaRoot).
License caps: up to 40 dispensaries and 8 cultivators (AlphaRoot).
Approximate licensees: about 38 dispensaries operating as of late 2025; 8 cultivators authorized (Marijuana Herald).
Patients: about 115,275 registered as of March 2026 (Marijuana Herald).
Sales: record of about 291.1 million dollars in 2025 (Camden News).
Dispensary annual renewal fees and exact residency rules are unconfirmed in current sources; verify with the Medical Marijuana Commission.

Enclosure read

Arkansas is heavily fenced. A statutory cap of 8 cultivators and roughly 40 dispensaries, combined with steep capital and bonding thresholds (a 1 million dollar bond or assets and 500,000 dollars liquid for a grow license), concentrates a 291-million-dollar market in a handful of well-capitalized operators while shutting out small growers and equity applicants. Home grow is banned, removing the decentralized release valve. The intoxicating-hemp ban (Act 629 and Act 934) further closes the lower-barrier hemp channel that small retailers and gas stations had used, pushing all legal THC commerce into the capped dispensary system. The governor's repeated vetoes of access-expansion bills keep the system tight, and there is no social-equity carve-out. The main counterweight is the citizen-initiative process, which keeps some democratic pressure alive even though the 2024 attempt was struck on ballot-language grounds. On balance this is consolidated and fenced, justifying a 4 out of 5. It is not a 5 because the initiative pathway and an active reform-leaning legislator preserve a route to change.

What to watch next

November 12, 2026: federal hemp restrictions take effect, aligning federal law with Arkansas's existing ban (Herb).
Hemp enforcement: continued DFA seizures and any litigation responses to Act 934 (Arkansas AG).
2027 regular session: the next realistic window for cannabis, hemp, or psychedelic legislation, since 2026 was a fiscal-only session (Ballotpedia 2026 session).
Ballot watch: whether Arkansans for Patient Access or others refile a cannabis amendment for a future cycle; monitor petition activity and signature deadlines via the Arkansas Secretary of State.
November 2026 election: gubernatorial and legislative races that could shift the reform calculus.

Regulators

Arkansas Medical Marijuana Commission, housed under the Department of Finance and Administration, licenses dispensaries and cultivators (DFA MMC).
Arkansas Department of Finance and Administration (DFA): hemp enforcement, seizures, and tax administration (Marijuana Moment).
Arkansas Attorney General (Tim Griffin): certification and enforcement of the hemp ban (Arkansas AG).
Arkansas Department of Health: original oversight role under the medical amendment (mmj.com).

Federal exposure (2026)

Arkansas is a medical-only cannabis state with no adult-use program, no home grow, and a hard ban on intoxicating hemp, which shapes how each federal lever lands here.

Rescheduling and 280E: The DOJ/DEA order signed April 22, 2026 and effective April 28, 2026 (91 FR 22714) moved only FDA-approved cannabis drugs and state-licensed medical cannabis from Schedule I to Schedule III; recreational cannabis stays Schedule I. Because Arkansas licenses cannabis only for medical purposes, its entire licensed market falls inside the category that gained relief. The order was signed April 22, 2026 and became effective April 28, 2026, ending the Section 280E tax penalty for state-licensed medical operators going forward, meaning Arkansas's roughly 38 dispensaries and 8 cultivators can now deduct ordinary business expenses (salaries, rent, insurance, supplies) they were previously denied. Industry and local reporting put the prior 280E burden at roughly 30 to 40 percent in extra federal tax, so the relief is materially favorable to the existing capped operators (Arkansas Business; KTLO; Foley Hoag; Federal Register order). Important limits: Schedule III does not legalize cannabis, does not authorize interstate commerce, and does not reach recreational businesses, so the relief is purely a tax effect for Arkansas's medical incumbents, not a market opening. The acting attorney general also encouraged Treasury to consider retrospective 280E relief for prior years, which is not yet guaranteed (Foley & Lardner). A broader DEA rescheduling hearing on all cannabis opened June 29, 2026, and may slip into 2027; if all cannabis were eventually rescheduled, the medical-recreational line that currently favors Arkansas's medical-only structure would blur, but no such outcome exists yet.

Hemp cliff (November 12, 2026): FY2026 agriculture appropriations (Sec. 781, sponsored by Rep. Andy Harris, R-MD) narrowed the federal hemp definition to a total-THC standard of about 0.4 milligrams of THC per container, recriminalizing roughly 90 to 95 percent of intoxicating hemp products effective November 12, 2026. A delay bill, H.R.7010, was not enacted, and the 2026 Farm Bill (H.R.7567) keeps the ban. For Arkansas the practical effect is minimal because the state already banned intoxicating hemp under Act 629 of 2023 and Act 934 of 2025, with the Eighth Circuit clearing the injunction in June 2025 and DFA enforcement live. Arkansas is therefore already aligned with the federal cliff; the federal change removes the out-of-state supply and online channels that Arkansas consumers and gray-market sellers might still have reached, hardening a prohibition the state has already chosen rather than forcing any new state action (Herb; Frier Levitt).

Banking: SAFER Banking remains stalled in Congress, so Arkansas's licensed medical operators still face the same banking and access-to-capital friction as the rest of the industry. Schedule III status does not by itself resolve banking access, so for now the 280E tax relief is the main federal benefit Arkansas operators see, without a parallel banking fix.

Psychedelics: Arkansas has no decriminalization or therapeutic-access program, so the federal pathway is the only near-term route to any legal psychedelic access in the state. Psilocybin, MDMA, and ibogaine remain Schedule I; an April 18, 2026 executive order, Accelerating Medical Treatments for Serious Mental Illness [https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/] plus FDA priority vouchers are fast-tracking FDA review, but no approval has issued, and conditional rescheduling triggers only on FDA approval. Practically, nothing changes in Arkansas until and unless the FDA approves a psychedelic therapy, at which point a controlled, medicalized channel could appear without any state legislation (recovered.org).

Harm reduction: Arkansas is a partial harm-reduction state (naloxone over the counter, fentanyl test strips legalized in 2023, syringe services only impliedly permitted). The SAMHSA guidance change of April 24, 2026 bars federal funds for fentanyl test strips, clean syringes, and sterile water, while still supporting naloxone. Arkansas programs that rely on federal dollars for test strips or syringe supplies are exposed to those cuts, even though the underlying state legality of test strips and naloxone is unchanged; the federal funding withdrawal could shrink the practical reach of the very tools Arkansas only recently legalized, while naloxone distribution remains fundable (NACo; NEXT Distro). Fentanyl itself remains permanently Schedule I under the HALT Fentanyl Act of July 2025, reinforcing the criminal-enforcement posture that surrounds Arkansas's possession laws.

Patient access and rights

This section covers what Arkansas law does and does not protect for a medical cannabis patient: use inside a hospital, and the broader rights that follow a patient into work, housing, parenting, an organ transplant list, and school. It is information, not legal advice, and it reflects the law as of July 2026. Each point links to the primary statute.

Hospital access (Ryan's Law): Arkansas has no hospital-access law. No statute requires a hospital, nursing home, or hospice to let a qualifying patient use medical cannabis on site, so whether a facility allows it is left to that facility's own policy, and many refuse. Seven states have now enacted a Ryan's Law protection (California in 2021, and Colorado, Delaware, Louisiana, Oregon, Virginia, and Washington in 2026), and Pennsylvania has a bill pending; Arkansas is not among them. The absence is the finding: an Arkansas patient has no enforceable right to use their medicine in a hospital today.

Broader protections: Arkansas places its patient protections in the state constitution, which makes them harder to repeal than an ordinary statute. Amendment 98, Section 3, protects a qualifying patient across all six areas. It bars employment discrimination against a qualifying patient (Section 3(f)(3)), bars a landlord or a school from penalizing a person solely for being a qualifying patient (Section 3(f)(1)), protects parental rights (Section 3(g)), and provides for the purposes of medical care, including organ transplants, that authorized use is treated as the equivalent of any other prescribed medication (Section 3(f)(2)). An Arkansas patient cannot be denied a transplant listing solely for lawful medical cannabis use.

Out-of-state patients: Arkansas offers a temporary visiting-patient card, valid for 90 days, that lets an out-of-state patient purchase at an Arkansas dispensary.

The federal picture: the April 2026 federal move of state-licensed medical cannabis to Schedule III did not change any of this. Schedule III does not make dispensary cannabis a lawful prescription medicine and does not create any hospital-use right; only state law can force hospital access, and Arkansas has not enacted a Ryan's Law. The broader protections above are a creature of Arkansas law, not federal law.

Sources: Arkansas patient protections, Arkansas Constitution, Amendment 98, Section 3.

Analysis: the enclosure read in depth

Arkansas is one of the more tightly enclosed drug-policy environments in the country, and the 2026 federal moves mostly tighten the fence rather than open it. The people fenced out are the same at both levels of government: small cultivators and retailers, equity applicants, home growers, and the informal hemp economy. At the state level the cannabis market is capped at 8 cultivators and roughly 40 dispensaries, gated by a 1 million dollar bond-or-assets requirement and 500,000 dollars in liquid assets for a grow license, with no social-equity carve-out and no home grow. That structure concentrates a record 291 million dollar market in a handful of well-capitalized incumbents. Governor Sanders has actively defended this perimeter, vetoing even modest access-expansion measures like HB1889 (dispensary delivery and drive-through windows), and the legislature's 2026 fiscal-only session filed no cannabis, hemp, or psychedelic bills, so there was no state-level pressure toward opening.

The state-plus-federal interaction is where the enclosure read sharpens. The April 2026 Schedule III order hands Arkansas's capped medical incumbents a real prize, the end of 280E, worth an estimated 30 to 40 percent in federal tax, but it hands that prize only to entities already holding one of the scarce state licenses. The federal benefit flows to incumbents and is structurally unavailable to anyone the state has already fenced out, so rescheduling deepens the moat rather than widening the gate. The November 12, 2026 hemp cliff does the same from the other direction: Arkansas already banned intoxicating hemp, and the federal total-THC standard now closes the out-of-state and online supply that small sellers might have leaned on, pushing all legal THC commerce into the capped dispensary channel. Banking stagnation (stalled SAFER Banking) keeps capital access tight, which again favors operators who already have it. The SAMHSA harm-reduction cuts pull federal money away from test strips and syringes, narrowing the one genuinely decentralized, low-barrier public-health channel, while naloxone, the most controllable tool, keeps its funding. Across cannabis, hemp, harm reduction, and capital, the consistent direction is medicalize-and-control and consolidate around large incumbents.

What to watch: whether Treasury grants retrospective 280E relief (a further windfall to incumbents); whether the broader DEA rescheduling hearing that opened June 29, 2026 advances or slips to 2027 and eventually blurs the medical-only line that currently advantages Arkansas's structure; any litigation response to Act 934; whether the SAMHSA cuts force Arkansas harm-reduction programs to scale back; and the November 2026 elections, where Sanders is a strong favorite, suggesting continuity of the current posture. The near-absence of commons counter-moves is the defining feature here: there is no home grow, no social-equity program, no decriminalization, no psychedelic-access framework, and no active reform legislation. The one live commons lever is the citizen-initiative process, which keeps a democratic route open, but the 2024 medical-expansion measure was struck on ballot-language grounds and no confirmed 2026 measure has surfaced, so even that channel is currently dormant.

The enclosure score of 4 out of 5 holds under both state and federal dynamics. The state alone justifies a high score through caps, capital barriers, no home grow, gubernatorial vetoes, and no equity program; the 2026 federal layer reinforces it by routing tax relief, supply, and capital toward existing license holders while pulling funding from low-barrier harm-reduction tools. It is not a 5 because the citizen-initiative pathway remains legally available and a reform-leaning legislator (Rep. Aaron Pilkington) is still active, preserving a structural, if presently quiet, route to change. Should the initiative channel go fully dormant and the broader federal rescheduling stall in a way that locks in the medical-incumbent advantage, the case for a 5 would strengthen.

Active legislation (2026)

The 2026 session was a short fiscal session centered on the budget, plus a special session called by the governor for income-tax cuts; no cannabis, hemp, psychedelic, or drug-policy bills were filed in it. The most significant recent drug-policy actions are 2025 enactments that became operative in 2026. This list is not exhaustive; for the long tail and live status, see LegiScan Arkansas, the Arkansas General Assembly.

Beyond the live tracker

These measures are not in the live bill list below: some are not bills (executive orders, rules, referendums, or budgets), and some are proposals or prior-session measures the live tracker does not currently carry.

Act 934 (2025) Expanded ban on intoxicating hemp-derived products (Delta-8, Delta-9, etc.) (Signed Apr 21, 2026; certified effective Apr 22, 2026)
Act 629 (2023) Original ban on intoxicating hemp products; enforcement cleared by 8th Circuit June 2025 (In effect / enforced)
SB485 (2025) Narrowly tailored probation conditions (Enacted (2025))

Bill	Title/Topic	Chamber	Status	Sponsor(s)
Act 934 (2025)	Expanded ban on intoxicating hemp-derived products (Delta-8, Delta-9, etc.)	Enacted	Signed Apr 21, 2026; certified effective Apr 22, 2026	Unconfirmed
Act 629 (2023)	Original ban on intoxicating hemp products; enforcement cleared by 8th Circuit June 2025	Enacted	In effect / enforced	Unconfirmed
HB1889 (2025)	Dispensary delivery and drive-through windows	House	Vetoed by Gov. Sanders, Apr 2025	Rep. Aaron Pilkington (R-Knoxville), lead sponsor
SB485 (2025)	Narrowly tailored probation conditions	Senate	Enacted (2025)	Unconfirmed

Support this work

This work is free and reader-funded. No paywalls, no ads. This brief is independent and fully sourced, and reader contributions are what keep the 50-state coverage current and answerable to readers, not advertisers or owners.

If it helped you, please chip in $5 to keep it going. Recurring support helps most; about $25 funds a full refresh of a state brief like this one.

Contribute $5 on Ko-fi Become a member

← Back to all 50 states and federal briefs

A planning snapshot for 2026, not legal advice. Policy moves quickly; confirm any single detail against the cited sources before acting on it. Sponsor names are given where confirmable and marked unconfirmed otherwise.

About the author. Jessica Mantonya is the founder of Drug Policy Watch and Hold in Common. She also advises operators, advocates, and funders on regulatory strategy and anti-enclosure positioning. Work with her →